Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study comapre Docecal and Taxotere in metastatic breast cancer

Trial Profile

Phase 1 study comapre Docecal and Taxotere in metastatic breast cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2018

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics; Registrational
  • Sponsors Oasmia Pharmaceutical
  • Most Recent Events

    • 31 Aug 2018 According to an Oasmia Pharmaceutical media release, two studies (CTP 293315 and CTP 293313) will form the basis of discussion with other authorities such as EMA for Europe and the FDA for the US.
    • 31 Aug 2018 According to an Oasmia Pharmaceutical media release, two studies (CTP 293315 and CTP 293313 ) were started in 2016 and the last of a total of 228 patients at 17 clinics in 5 countries has now completed treatment.
    • 22 Feb 2018 According to an Oasmia Pharmaceutical media release, 228 patients had been enrolled in two studied of Docecal in comparison with Taxotere (CTP 293315 and CTP 293313 ) from 17 clinical sites in five countries.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top